MIMEDX GROUP INC (MDXG) Stock Price & Overview

NASDAQ:MDXG • US6024961012

Current stock price

4.12 USD
-0.05 (-1.2%)
At close:
4.11 USD
-0.01 (-0.24%)
After Hours:

The current stock price of MDXG is 4.12 USD. Today MDXG is down by -1.2%. In the past month the price decreased by -20.31%. In the past year, price decreased by -48.11%.

MDXG Key Statistics

52-Week Range4.08 - 8.115
Current MDXG stock price positioned within its 52-week range.
1-Month Range4.08 - 5.46
Current MDXG stock price positioned within its 1-month range.
Market Cap
612.108M
P/E
10.05
Fwd P/E
35.64
EPS (TTM)
0.41
Dividend Yield
N/A

MDXG Stock Performance

Today
-1.2%
1 Week
-5.94%
1 Month
-20.31%
3 Months
-41.56%
Longer-term
6 Months -41.31%
1 Year -48.11%
2 Years -46.49%
3 Years +20.82%
5 Years -60.00%
10 Years N/A

MDXG Stock Chart

MIMEDX GROUP INC / MDXG Daily stock chart

MDXG Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to MDXG. When comparing the yearly performance of all stocks, MDXG is a bad performer in the overall market: 93.28% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MDXG Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to MDXG. MDXG scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MDXG Earnings

On February 25, 2026 MDXG reported an EPS of 0.1 and a revenue of 118.09M. The company beat EPS expectations (16.71% surprise) and beat revenue expectations (8.43% surprise).

Next Earnings DateApr 28, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$0.10
Revenue Reported118.095M
EPS Surprise 16.71%
Revenue Surprise 8.43%

MDXG Forecast & Estimates

12 analysts have analysed MDXG and the average price target is 9.86 USD. This implies a price increase of 139.32% is expected in the next year compared to the current price of 4.12.

For the next year, analysts expect an EPS growth of -71.81% and a revenue growth -14.71% for MDXG


Analysts
Analysts81.67
Price Target9.86 (139.32%)
EPS Next Y-71.81%
Revenue Next Year-14.71%

MDXG Groups

Sector & Classification

MDXG Financial Highlights

Over the last trailing twelve months MDXG reported a non-GAAP Earnings per Share(EPS) of 0.41. The EPS increased by 41.38% compared to the year before.


Income Statements
Revenue(TTM)418.63M
Net Income(TTM)48.58M
Industry RankSector Rank
PM (TTM) 11.6%
ROA 14.18%
ROE 18.94%
Debt/Equity 0.06
Chartmill High Growth Momentum
EPS Q2Q%100%
Sales Q2Q%27.11%
EPS 1Y (TTM)41.38%
Revenue 1Y (TTM)19.99%

MDXG Ownership

Ownership
Inst Owners73.14%
Shares148.57M
Float145.88M
Ins Owners1.74%
Short Float %4.6%
Short Ratio6.86

About MDXG

Company Profile

MDXG logo image MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 808 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.

Company Info

IPO: 2007-08-20

MIMEDX GROUP INC

1775 W Oak Commons Court, Ne

Marietta GEORGIA 30062 US

CEO: Timothy R. Wright

Employees: 837

MDXG Company Website

MDXG Investor Relations

Phone: 17706519100

MIMEDX GROUP INC / MDXG FAQ

Can you describe the business of MIMEDX GROUP INC?

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 808 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.


Can you provide the latest stock price for MIMEDX GROUP INC?

The current stock price of MDXG is 4.12 USD. The price decreased by -1.2% in the last trading session.


Does MDXG stock pay dividends?

MDXG does not pay a dividend.


What is the ChartMill technical and fundamental rating of MDXG stock?

MDXG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Is MIMEDX GROUP INC (MDXG) expected to grow?

The Revenue of MIMEDX GROUP INC (MDXG) is expected to decline by -14.71% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the number of employees for MIMEDX GROUP INC?

MIMEDX GROUP INC (MDXG) currently has 837 employees.